betaxolol [Oral]

Adult Dosing

Hypertension

Usual dose 10-20 mg PO qd
Initial dose 10 mg PO qd; Increase dose if desired response is not achieved after 7 to 14 days
Max: 40mg PO qd

Note:

If therapy is withheld, it should be achieved gradually over a period of about 2 wks

Pediatric Dosing

Safety and effectiveness in pediatric patients have not been established

[Outline]

Adult Dosing
Pediatric Dosing

Indications ⬆ ⬇

For management of hypertension, used as monotherapy or concomitantly with other antihypertensive agents, particularly thiazide type diuretics

Contraindications ⬆ ⬇

Hypersensitivity to any of the ingredients of the product
Sinus bradycardia
Heart block greater than first degree
Cardiogenic shock
Overt cardiac failure
Pheochromocytoma
Abrupt withdrawal
Sick sinus syndrome without pacemaker

Black Box Warnings ⬆ ⬇

Dosing Adjustment ⬆ ⬇

Renal Dose Adjustments

Sever renal impairment: Initial dose 5 mg PO qd
Increase dose if desired response is not achieved by 5 mg PO qd x 2wks
Max: 20 mg PO qd

Hepatic Dose Adjustments

Hepatic impairment: No dose adjustments

Warnings/Precautions ⬆ ⬇

Therapy should be administered carefully in hypertensive patients who have CHF controlled by digitalis and diuretics. Both digitalis and beta-adrenergic receptor blocking agents slow AV conduction
Continued depression of the myocardium with betaxolol can lead to cardiac failure, if first signs or symptom of cardiac failure occurs discontinue the therapy
Worsening of angina pectoris and myocardial infarction have been reported in patients who have interrupted therapy, if withdrawal symptoms occur patient should be carefully observed and therapy should be reinstituted for temporary purpose, patients should be warned against interruption of therapy without the physician's advice
Patients with bronchospastic disease should not receive betaxolol
Withheld of a betaxolol prior to major surgery is controversial. It has been reported that therapy increases the risk of excessive myocardial depression during general anesthesia and difficulty in restarting and maintaining the heart beat
Care should be taken if treatment is continued especially when using anesthetic agents which depress the myocardium; such as ether, cyclopropane, and trichloroethylene
Patient of developing thyrotoxicosis should be carefully managed to avoid abrupt withdrawal of therapy to prevent from precipitation a thyroid storm

Cautions: Use cautiously in

Bronchospastic patient
Peripheral vascular disorder
Major surgery
Diabetes mellitus
Thyroid disorder
WPW syndrome
Sever renal impairment
Psoriasis
Pregnancy 2nd or 3rd trimester
Breastfeeding
Myasthenia gravis
History of severe anaphylactic reaction
Elderly patients

Pregnancy/Breast Feeding ⬆ ⬇

Pregnancy Category:C

Breastfeeding: Because of its relatively extensive excretion into breastmilk and minimal reported experience during breastfeeding, other beta-blocking agents may be preferred for systemic use, especially while nursing a newborn or preterm infant, based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 15 March 2011). Manufacturer advises caution.

Adverse Reactions ⬆ ⬇

CV: CHF, heart block, bradycardia, Raynaud phenomenon
RESP: Bronchospasm, URI, dyspnea
CNS: Headache, dizziness, insomnia, weakness, anxiety, drowsiness, memory loss, mental status changes, nightmares
PSYCHIATRY: Nervousness, depression
EENT: Pharyngitis, rhinitis, blurred vision, stuffy nose
GI: Dyspepsia, diarrhea, nausea, constipation, diarrhea, increased liver enzymes, vomiting
DERM: Exacerbation of psoriasis, rash, lupus erythematosus
ENDO: Hyperglycemia, hypoglycemia
MUSC: Arthralgia, chest pain, back pain, joint pain
REPRODUCTION: Erectile dysfunction, decreased libido, impotence
MISC: Fatigue, lethargy

Clinical Pharmacology ⬆ ⬇

Sympatholytics; blocks catecholamine stimulation of beta 1-adrenergic receptors in the heart and vascular smooth muscle
Orally absorbed with absolute bioavailability of 89%
Metabolized by liver; CYP450; unknown
Excretion: >80% urine (15% unchanged)
Half life: 14-22 hrs

Brands and Availability ⬆ ⬇

US Trade Name(s)

Only generic available

US Availability

betaxolol (generic)

TABS: 10, 20 mg

Canadian Trade Name(s)

Canadian Availability

UK Trade Name(s)

UK Availability

Australian Trade Name(s)

Australian Availability

[Outline]

Classification ⬆ ⬇

Cardiovascular

Beta-adrenergic Blockers
Cardioselective

Pricing ⬆ ⬇

Pricing data from www.DrugStore.com in U.S.A.

Betaxolol HCl 10 MG TABS [Bottle] (KVK TECH)
30 mg = $44.99
90 mg = $113.97

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.

Pill ⬆

Drug Name: Kerlone 10 MG Oral Tablet

Ingredient(s): Betaxolol

Imprint: KERLONE;10

Color(s): White

Shape: Round

Size (mm): 9.00

Score: 2

Inactive Ingredient(s): hydroxypropyl methylcellulose / lactose / magnesium stearate / microcrystalline cellulose / polyethylene glycol 400 / colloidal silicon dioxide / sodium starch glycolate / titanium dioxide

Drug Label Author:
sanofi-aventis U.S. LLC

DEA Schedule:
Non-Scheduled

Drug Name: Kerlone 20 MG Oral Tablet